The report on Metabolic Disorders Therapeutics
Market by disease type (diabetes, obesity,
hypercholesterolemia and lysosomal storage disease), product (metachromatic leukodystrophy, globoid
leukodystrophy, hepatic encephalopathy and others) trends analysis and forecasts up to 2023 studies the
market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-
Pacific, Rest of the World. According to the report the Global Metabolic Disorders Therapeutics Market is
projected to grow at a CAGR of 5.7% in terms of value over the period of 2017-2023. The growth in the world
market is primarily driven by significant contribution by North America (Leading region) region to this market.
Get a Sample Request
https://www.infiniumglobalresearch.com/reports/sample_request/145
Metabolism is a process in which human body generates energy from the food humans eat. The food that
humans consume comprises proteins, carbohydrates, and fats. Chemicals in human digestive system break the
food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in human
body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by
enzymes. Any disturbance in the pathways involved in the development and metabolism of carbohydrates,
proteins, and fats, leads to metabolic disorder.
Market Insights
Increase in academia-industry collaborations for drug developments is the key factor responsible for the
growth of metabolic disorder therapeutics market. Furthermore, growing diabetic population is significantly
contributing to the growth of this market. Low compliance, adherence rate for metabolic disorder therapies
and availability of alternative treatment option are the major challenges faced by the players operating in this
market. The global metabolic disorder therapeutics market is anticipated to present several opportunities of
growth of market size over the forecast period due to strategic collaborations and acquisition and increased R
& D investment.
Infinium Global Research